NCT03658304已完成2 期
A Single Arm Phase II Trial of the Intraoperative Intravesical Instillation of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- Bladder Tumor Recurrence Rate
研究概览
简要总结
Results of previous studies suggest that the timing of intravesical mitomycin C administration may impact bladder tumor recurrence rate following radical nephroureterectomy. This is the first study of its kind to attempt to identify the importance of timing of mitomycin C administration relative to bladder tumor recurrence rate following radical nephroureterectomy.This study will investigate the one year bladder tumor recurrence rate in patients with urothelial carcinoma of the upper urinary tract following intraoperative administration of mitomycin C during a nephroureterectomy, as well as the time to bladder tumor recurrence in this patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Both males and females ≥ eighteen years of age
- •Clinical diagnosis of urothelial carcinoma of the renal pelvis and/or ureter. Clinical diagnosis of urothelial carcinoma may be based upon radiographic, pathologic or cytological findings alone or in combination with one another. No other histology is allowed.
- •The TNM stage of the subject's disease (using the American Joint Committee on Cancer [AJCC] Cancer Staging Manual, 8th Edition) must be Tis, Ta, T1, T2, or T3, N0, M
- •Subjects may have either a high-grade or low-grade tumor.
- •ECOG performance status of 0-2
- •Written informed consent obtained from the subject and the ability for the subject to comply with all the study-related procedures.
- •Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy prior to and for at least 3 months after mitomycin C instillation to minimize the risk of pregnancy. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
- •Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) should avoid conceiving children prior to and for 3 months following mitomycin C instillation
- •Subjects must have hemoglobin ≥ 9 g/dL and a platelet count ≥ 100,000/μL.
排除标准
- •Active urothelial carcinoma of the bladder within 12 months prior to enrollment
- •History of adverse reaction to mitomycin C
- •Evidence of regional or metastatic disease.
- •History of radical cystectomy
- •Planned radical cystectomy at the time of nephroureterectomy
- •Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy prior to and for at least 3 months after mitomycin C instillation.
- •Females who are pregnant or breastfeeding.
- •History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
- •Prisoners or subjects who are involuntarily incarcerated.
- •Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
- •Subjects demonstrating an inability to comply with the study and/or follow-up procedures
研究组 & 干预措施
Mitomycin C
Experimental
干预措施: Mitomycin c (Drug)
结局指标
主要结局
Bladder Tumor Recurrence Rate
时间窗: 1 year
The bladder tumor recurrence rate will be measured by the percentage of subjects who are confirmed by bladder biopsy to have a recurrence of urothelial carcinoma in the bladder following nephroureterectomy
次要结局
- Time to Bladder Tumor Recurrence(3 years)
- Percentage of Subjects Who Had a Bladder Tumor Recurrence 3 Years Post-operatively(3 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral StrictureUrethral StrictureNCT06232005Ain Shams University50
尚未招募
3 期
Role of pre procedure mitomycin C inside the bladder in treatment in patients with recurrent Non invasive bladder cancerCTRI/2024/05/067430AIIMS bhubaneswar
已完成
不适用
Rationalizing use of antimetabolites in glaucoma surgeryCTRI/2018/04/013200Postgraduate Institute of Medical Education and Research70
已完成
2 期
Intravesical Adjuvant Electromotive Mitomycin-CBladder Cancer TNM Staging Primary Tumor (T) TaBladder Cancer TNM Staging Primary Tumor (T) T1Bladder Cancer Transitional Cell GradeNCT01920269University of Rome Tor Vergata331
招募中
不适用
Effect of a SI-MMC on the IVR Rate After Ureteroscopy for UTUCUpper Urinary Tract CarcinomaNCT05731622Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)100